Voting Results of the Annual General Meeting held on 17th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evoq Remedies held its Annual General Meeting on 17th September 2025 via video conferencing, lasting just 8 minutes (4:00 PM to 4:08 PM). Out of 1,653 total shareholders, only 20 attended (6 promoter group, 14 public). Of 24.9 lakh total outstanding shares, only 12.47% (31.04 lakh shares) were polled. Of 11 resolutions, only 3 passed — adoption of FY25 audited financial statements (98.71% in favor), re-appointment of Managing Director Bhumishth Patel (91.37%), and appointment of M/s H Thakkar & Co. LLP as statutory auditor (91.49%). All 8 related party transaction resolutions — with Poshan Nutriwell, Solaris Agritech, Recurso Wellness, EL Faro Ventures, Vogue Lifestyle, Patron Exim, Solis Inventions, and Atlantis Exim — FAILED because promoters' 27.92 lakh votes were declared invalid (due to their interest), and 85.9% of public votes (268,000 out of 312,000 polled) voted against them.
This is a significant negative signal for shareholders. Two-thirds of the resolutions failed due to strong public dissent against related party transactions, suggesting governance concerns or shareholder discomfort with these deals. Retail investors should note the very low voting turnout from public shareholders (only 1.41% of public shares voted) but high rejection rate among those who did. The failed RPTs may need to be re-proposed or restructured, and continued opposition could weigh on stock sentiment.